Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-26366821 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
| Arm | Type | Description |
|---|---|---|
| Cohort1: JNJ-2636682/Placebo | EXPERIMENTAL | Participants will receive single dose of JNJ-26366821 or placebo on Day 1. |
| Cohort 2: JNJ-26366821/Placebo | EXPERIMENTAL | Participants will receive single dose of JNJ-26366821 or placebo on Day 1. |
| Cohort 3: JNJ-26366821/Placebo | EXPERIMENTAL | Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2. |
| Name | Type | Description |
|---|---|---|
| JNJ-26366821 | DRUG | Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC). |
| Placebo | DRUG | Participants will receive sodium chloride injection as placebo on Day 1. |
Inclusion Criteria: * Overall good health, on the basis of full physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening * Body weight 50 - 100 kilogram (kg), body mass index (BMI) 18 - 30 kilogram per meter square (kg/m\^2), inclusive at screen...
JNJ-26366821 is an investigational small molecule being developed by Johnson & Johnson (JNJ). It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other.
JNJ-26366821 is being studied for use in healthy participants. It is an investigational small molecule in Phase 1 clinical development. The drug has not been approved for any indication and remains in clinical testing.
JNJ-26366821 is developed by Johnson & Johnson, a company traded on the stock exchange under the ticker JNJ. The drug is an investigational small molecule currently in Phase 1 clinical development.
JNJ-26366821 is in Phase 1 clinical development. It is an investigational small molecule being studied in healthy participants. The drug is not approved and remains in clinical testing.
JNJ-26366821 has been studied in a Phase 1 clinical trial with the identifier NCT03990519. This trial, titled "A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants," was completed in the United States and enrolled 33 participants.
JNJ-26366821 is an investigational small molecule developed by Johnson & Johnson. It is currently in Phase 1 clinical development and has been studied in healthy participants. No alternative names for this drug have been reported.